Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
Last trade$20.76
Day change-$0.18 (-0.86%)
Day range$20.57 – $21.97
Volume1,424,656
Market cap$2.17B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.17B
Price / earnings
—
Price / book
2.27×
Price / sales
14.78×
EV / sales
14.01×
EV / EBITDA
-5.54×
Profitability
Earnings per share
-$1.03
Return on assets
-8.44%
Return on equity
-11.24%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.11×
Current ratio
13×
Quick ratio
13×
Cash ratio
2.6×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$398.24M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BEAM, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$307K
$490K
$31.74M
$114.11M
$9.7M
$8.47M
$7.47M
$30.07M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$307K
$490K
$31.74M
$114.11M
$9.7M
$8.47M
$7.47M
$30.07M
Selling, general and administrative
$31.52M
$31.95M
$34.43M
$32.28M
$26.74M
$26.86M
$27.94M
$28.66M
Research and development
$110.11M
$95.1M
$104.52M
$99.28M
$109.77M
$101.76M
$98.82M
$101.44M
Total operating expenses
$141.63M
$127.25M
$138.95M
$131.55M
$136.51M
$128.65M
$126.76M
$130.1M
Operating income
-$141.32M
-$126.76M
-$107.22M
-$17.45M
-$126.81M
-$120.18M
-$119.29M
-$100.04M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$134.41M
-$122.68M
-$94.32M
$244.3M
-$112.57M
-$102.14M
-$108.33M
-$90.35M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$134.41M
-$122.68M
-$94.32M
$244.3M
-$112.57M
-$102.14M
-$108.33M
-$90.35M
Net income attributable to common shareholders
-$134.41M
-$122.68M
-$94.32M
$244.3M
-$112.57M
-$102.14M
-$108.33M
-$90.35M
EBITDA
-$135.88M
-$121.35M
-$101.61M
-$11.78M
-$121.25M
-$114.64M
-$113.76M
-$94.59M
Basic earnings per share
-$1.28
-$1.18
-$0.91
$2.37
-$1.10
-$1.00
-$1.23
-$1.09
Diluted earnings per share
-$1.28
-$1.18
-$0.91
$2.37
-$1.10
-$1.00
-$1.23
-$1.09
Recent news
Company coverage with links to the original publishers.
Beam Therapeutics reported positive top-line results from its BEACON study for risto-cel, a gene-editing therapy for sickle cell disease, achieving primary efficacy and safety endpoints with patients demonstrating freedom from severe vaso-occlusive crises for at least 12 consecutive months. The company plans to submit a biologics license application to the FDA by end of 2026, potentially marking the first commercial product approval for a base-editing therapy. Despite the encouraging clinical results, BEAM shares declined 7% following the announcement, likely due to concerns over weaker third-quarter results and profit-taking.
Over 45 pharmaceutical companies are advancing 50+ pipeline drugs for sickle cell disease treatment. Key developments include Agios Pharmaceuticals' mitapivat receiving FDA Priority Review, Novo Nordisk's etavopivat meeting Phase III endpoints, and CorrectSequence Therapeutics' CS-206 showing sustained vaso-occlusive crisis-free results. The pipeline features diverse mechanisms including PK activators, gene therapies, and fetal hemoglobin stimulants, with approximately 5+ drugs in late-stage development.
Beam Therapeutics (BEAM) shares surged 15.6% following positive early-stage data for its experimental gene-editing treatment BEAM-301 for glycogen storage disease type Ia. The treatment showed improvements in fasting tolerance and glucose control in six patients, with two patients no longer requiring daily starch supplements. Despite some serious adverse events, the company plans to test higher doses and pursue FDA approval discussions. However, earnings estimate revisions remain unchanged, which may limit sustained momentum.
Cathie Wood's Ark Invest added to positions in Meta Platforms, Airbnb, and Beam Therapeutics on Monday. Meta surged 11% on momentum from its new Muse AI app and an upgraded price target from Wells Fargo. Airbnb continues strong revenue growth despite headwinds from rising travel costs and regulatory scrutiny. Beam Therapeutics is recovering after recent clinical trial data showed efficacy in its gene-editing treatment for alpha-1 antitrypsin deficiency.
Beam Therapeutics announced management participation in three major investor conferences in September 2026. The company also reported progress on its BEAM-302 trial in Alpha-1 Antitrypsin Deficiency, with dosing completed for adult and adolescent patients and updated data selected for presentation at the European Respiratory Society Congress 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Feb 4, 2014
$0.225
Mar 3, 2014
recurring
Nov 4, 2013
$0.225
Dec 2, 2013
recurring
Aug 12, 2013
$0.23
Sep 3, 2013
recurring
May 6, 2013
$0.225
Jun 3, 2013
recurring
Feb 4, 2013
$0.225
Mar 1, 2013
recurring
Stock splits
Historical share-structure events and their execution dates.